Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LENSAR ( (LNSR) ) has shared an update.
On March 12, 2026, LENSAR, Inc. announced it had entered into a Priority Credit Line Agreement with Wells Fargo Bank, N.A., establishing a revolving, non-purpose margin credit facility of up to $50 million secured by a first-priority lien on a designated brokerage account. The company has deposited about $10 million in collateral to support borrowings, which may accrue interest at either a fixed rate tied to Treasury yields or a variable rate based on SOFR, and the agreement includes customary default provisions that could affect liquidity and capital flexibility if collateral values or payment obligations are not maintained.
The most recent analyst rating on (LNSR) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.
Spark’s Take on LNSR Stock
According to Spark, TipRanks’ AI Analyst, LNSR is a Neutral.
The score is primarily constrained by weak financial performance—deep losses, continued cash burn, and negative equity—despite strong recent revenue growth and healthy gross margins. Technical indicators are broadly neutral with limited trend strength, and valuation remains unattractive due to negative earnings and no dividend.
To see Spark’s full report on LNSR stock, click here.
More about LENSAR
LENSAR, Inc. operates in the medical technology sector, focusing on ophthalmic devices and solutions for eye care. The company’s offerings are geared toward supporting clinical practices and procedures, positioning it within the specialized market for vision-related medical equipment and services.
Average Trading Volume: 38,894
Technical Sentiment Signal: Buy
Current Market Cap: $140.8M
Find detailed analytics on LNSR stock on TipRanks’ Stock Analysis page.